| STICHTING HET NEDERLANDS KANKER INSTITUUT Patent applications |
| Patent application number | Title | Published |
|---|
| 20110269155 | Detecting Antigen Responsive Cells in a Sample - The present invention relates to methods for detecting antigen responsive cells in a sample using multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (NHC). Further, the present invention relates to the use of the present multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (MHC), for detecting antigen responsive cells in a sample, preferably a single sample, such as a blood sample. The present method allows high-throughput analysis of specific antigen responsive cells, such as T- and B-cells, thereby providing, for example, high-throughput methods for monitoring of diseases or conditions and the development of immunotherapeutics, vaccines, or the identification epitopes or immunogenic amino acid sequences. | 11-03-2011 |
| 20110097706 | MICRO-REACTOR FOR OBSERVING PARTICLES IN A FLUID - The invention relates to a micro-reactor for observing small particles, cells, bacteria, viruses or protein molecules in a fluid. The micro-reactor shows a first channel formed between two layers for containing the fluid, with an inlet and an outlet, the two layers separated by a first distance. A likewise second channel with an inlet and an outlet is placed adjacent to the first channel. A gap connects the first channel and the second channel, at the gap at least one layer showing a window transparent to the method of inspection and at the window the two layers being separated by a very small distance of, for example, 1 μm or less. | 04-28-2011 |
| 20100297624 | Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting Therapy - The invention is related to a method for determining whether an individual suffering from cancer is at risk of exhibiting or acquiring a reduced response towards HER2-targeting therapy. In one aspect, the invention utilizes the activity of a signal transduction pathway modulated by a lipid kinase for determining said risk. | 11-25-2010 |
